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Abstract
Background: Chordoid Meningioma is a rare brain tumour characterized
genetically by loss of genetic material from chromosome 22q at cytogenetic
level resulting in mutation of NF2 gene. Objectives and case report: In
the present report, we described a rare case of suprasellar chordoid
meningioma, which presented in a 32-year-old-woman. Her only complain
was throbbing headache. Neurological examination showed left temporal
hemianopia, decreased visual acuity (3/6), and no physical abnormalities
related to Castleman syndrome were noted. Cranial magnetic resonance (MR)
images demonstrated a 28x15 mm mass in the sellar region, which showed
iso-to low intensity that enhanced vividly after gadolinium with upwards
displacement of the Optic chiasm. Total surgical excision of the tumour was
performed and subsequent histological examination of the tumour showed
typical histology pattern of chordoid meningioma grade II according to the
WHO classification system of meningiomas. Genomic DNA was extracted
and mutation analysis for INI1 gene using primer of exon 4, 5, 7, and 9
showed mutation involving exon 9. DNA sequencing showed heterozygosity
C-T mutation in exon 9 of INI1 gene leading to change of amino acid serine
to phenylalanine at (codon 63). The details of this case are presented with a
review of the literature.
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1. Introduction
Chordoid meningioma, accounts for 0.5% of all intracranial meningiomas. It was first
described by Kepes et al., in 1988, and accepted as meningiomas variants by the WHO
classification of the central nervous system tumour in 19931,2.
Association of the tumour with haematologic abnormality such as microcytic
anaemia and dysgammaglobulinemia and/or Castleman syndrome have been repeat-
edly reported, especially, in paediatric patients [1], although chordoid meningioma
with no hematological abnormalities have also been reported [3, 4].
Microscopically chordoidmeningiomas have features ofmeningioma similar to chor-
doma which is usually characterized by epitheliod cord like tumour cells. It is classified
as WHO grade II tumour [5]. There are eosinophilic vacuolated cells within a myxoid
stroma and a lymphoplasmocytic infiltrate is often apparent and might be associated
with haematological abnormalities [6].
Cytogenetic analysis revealed that monosomy 22 is a common, early, and perhaps
primary event in the genesis of meningioma. Molecular analysis has identified several
important candidate genes. Of those, Neurofibromatosis 2 (NF2), Tumour Suppressor
in Lung Cancer-1 (TSLC1), and TP53 are the most commonly reported.
The INI1 (SMARCB1/hSNF5) gene, maps to chromosome 22q11.2, is part of the
SWI/SNF complex participating in transcriptional regulation by remodeling chromatin
in an ATP-dependent manner [7]. The SWI/SNF complex seems to be involved in
DNA replication [8]. These features characterize members of the SWI/SNF complex as
interesting targets for genes which may be involved in tumour formation.
Recently, INI1 has been shown to carry mutations predominately in some central
nervous system tumours such as meningiomas [9], schwannomas [10], astrocy-
tomas11, ependymomas12 and glioblastomas11). INI1, therefore, is an interesting
candidate gene for brain tumours, especially those entities that exhibit allelic loss
on chromosome 22.
2. Material and Methods
2.1. The Case
A 32-year-old-female lady presented with four months history of throbbing headache
and left visual field and acuity defect that worsened over the last three weeks. Neuro-
logical examination showed left temporal hemianopia, decreased visual acuity (3/6),
and no physical abnormalities related to Castleman disease.
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Routine laboratory investigations including Hb, MCV, MCH, total protein, albumen,
and globulin were all normal. MRI revealed large iso-intense sellar mass measuring
2.8?1.5 X1.5 cm that enhanced vividly after gadolinium with upwards displacement
of the Optic chiasm (Figure F1-A). A provisional preoperative diagnosis of a pituitary
macro adenoma was made. Preoperative assessment of T3, T4, TSH and prolactin
was normal. The patient was then operated upon through right sub frontal surgical
approach. Intraoperatively, a firm, circumscribed fibrous tumour with numerous vas-
cular feeders was found. Using the operating microscope, total excision of the tumour
and its dural attachment was attained according to Simpson classification grade I13.
Part of the tumour was fixed in 10% neutral formalin for histopathology examination.
The other part was kept for molecular studies.
2.2. Molecular Analysis
Genomic DNA was isolated using chloroform phenol extraction methods. PCR was
performed under standard conditions using dNTPs, Taq DNA polymerase (Promega,
Madison, Wisconsin, USA), and a Biometra UNO Thermoblock (Biometra, Gottingen,
Germany).
Primers of exon 4, 5, 7, and 9 for INI1 gene, were analyzed by SSCP and direct
sequencing employing a set of primers specified
Exon 4 forward primer, 5‘-TCA GGT CCT ATA CTG ACT GG-3‘.
Exon 4 reverse primer, 5‘-AGA ACT AAG GCG GAA TCA GC-3‘.
Exon 5 forward primer, 5‘-GCT TCC ATT TCA CTT TCA GC-3‘.
Exon 5 reverse primer, 5‘-GTT CCC ACG TAA CAC ACA GG-3‘.
Exon 7 forward primer, 5‘-CCTGGGCTGCAAAAGCTCTA-3‘
Exon 7 reverse primer, 5‘-GGAGGGAGAGACTCATGCAT-3‘
Exon 9 forward primer, 5‘-TGT TCC CAC CCC TAC ACT TG-3‘.
Exon 9 reverse primer, 5‘-ATG AAT GGA GAC GCG CGC TCT-3‘
PCR was performed in a final volume of 25 𝜇l containing 100 ng DNA, 50 mM KCl,
20 mM TRIS-HCl pH 8.4, 200 𝜇M of each dNTP, 0.1% gelatin, 10 pmol of each primer,
1.0–2.0 mM MgCl2 and 0.25 U Taq polymerase. Using touchdown programmed initial
denaturation at 94∘C for 1 min was followed by 40 cycles on an automated thermal
cycler (Biometra, Germany). These included denaturation at 94∘C for 35 s, annealing
at temperatures ranging from 58∘C to 62∘C depending on the primer pair for 40 s, and
extension at 72∘C for 40s followed by the final extension step at 72∘C for 10 min. The
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Figure 1
PCR products on acrylamide gel using SSCP analysis was performed on apparatus using
12% acrylamide gels. Electrophoresis was run at 2–6 W and variable temperatures.
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Figure 2
2.3. Sequencing
The same primers used for PCR analysis were used for sequencing. PCR products
samples were sent for commercial sequencing at Macrogen, Seoul, Republic of Korea.
The BLAST (Basic Local Alignment Search Tool) programmer at the site of National
Center for biotechnology Information (NCBI) was used for individual alignment of our
samples.
3. Results
Following surgery the patient had an uneventful postoperative recovery; the headache
subsided and the visual acuity markedly improved to 5\6. Postoperative values of T3,
T4, TSH and prolactin were within normal ranges.
Microscopic examination of the tumour specimen revealed cluster of cohesive cells
with dark regular nuclei and tapering cytoplasm arranged in a fibrous stroma showing
an intense lymphocytic and plasma cells infiltration. There were scattered Russell bod-
ies in the inflammatory reaction (Figure 2). The diagnosis of chordoid meningiomawith
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inflammatory reaction WHO Grade II was made and hence the patient was submitted
to conformal radiotherapy [14, 15]. The postoperative MRI revealed total removal of
the tumour (Figure F1-B).
3.1. Molecular results
The sequencing indicated that the mutation was heterozygotic with heterozygosity C-
T mutation in exon 9 of INI1 gene, the mutation changed in the amino acid serine to
phenylalanine in (codon 63) in this polymorphism data not reported in data analysis
programmer.
4. Discussion
Schmitz and co-workers have suggested an important role of INI1 gene in the patho-
genesis of meningioma16. This suggestion led many to speculate that NF2 is not the
only important gene in the pathogenesis of meningioma17. However, INI1 mutations
were seen in only four tumours out of 126 meningiomas16. Interestingly, INI1 muta-
tions in all four cases were in the same position: nucleotide 377 (Arg to His substitu-
tion). This intriguing finding prompted others to check the status of INI1 hot spots of
exons 4, 5, 7 and 9 in meningioma. However, all these studies were based in Europe
and USA, thus no such a study was performed in African population. Considering the
differences in clinical, histopathological, and the natural history of meningiomas in the
two populations, one may anticipate differences in the genetic profile as well.
Meningiomas can potentially occur at any site in the meninges. However, the most
common locations known are the parasagittal and falcine tumours that account for
around 24% of meningiomas, convexity tumours in 18%, olfactory groove, and tuber-
cular sellae seen in 10% each. Suprasellar chordoid meningioma is a rare tumour that
maymimic pituitary adenomas. In the present case, the clinical presentation was dom-
inated by headache and visual deterioration. The MRI finding was consistent with a
pituitary adenoma. Association of chordoid meningioma and Castleman syndrome has
been reported [18, 19]. The present case did not show features of Castleman syndrome.
Chordoid meningioma is a rare variant of meningioma; the differential diagnosis
includes glioma, myxoid chondrosarcoma, chondroid chordoma, and other variants of
meningiomas [4, 19–21]. Usually they show trabeculae or cords of eosinophilic vacuo-
lated cells in myxoid matrix [22].
The fact that the tumour proved to be chordoid meningioma should alert attention
to this possibility in interpretation of suprasellar tumours. More-over, WHO grade II
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meningiomas are considered to have an aggressive course. In the present report, there
were no features of an aggressive behavior; this might be due to early detection of
the tumour. The aggressive behaviour and the fibrous texture of these tumours with
its close anatomical relation to the vital structures in the sellar region render tumour
recurrence a potential risk. Use of post-operative radio therapy lessens the chance
of recurrence. Close and regular follow up of these patients is mandatory to detect
such recurrence. conclusion: The general belief from the clinical point of view that
meningiomas are benign tumours has to be accepted with great care, since only the
histological diagnosis can verify the potential aggressive behaviour of the tumour and
the subsequent liability for recurrence.
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